NEXALIN TECHNOLOGY INC (NXL) Stock Fundamental Analysis
USA - NASDAQ:NXL - US65345B2016 - Common Stock
1.5 USD
-0.03 (-1.96%)
1.5283 USD
+0.03 (+1.89%)
We assign a fundamental rating of 3 out of 10 to NXL. NXL was compared to 189 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for NXL as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, NXL is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
NXL had negative earnings in the past year.
NXL had a negative operating cash flow in the past year.
NXL had negative earnings in each of the past 5 years.
In the past 5 years NXL always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -134.84%, NXL is doing worse than 83.07% of the companies in the same industry.
NXL has a Return On Equity of -148.42%. This is in the lower half of the industry: NXL underperforms 67.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -134.84% | ||
| ROE | -148.42% | ||
| ROIC | N/A |
ROA(3y)-110.33%
ROA(5y)-801.91%
ROE(3y)-127.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NXL has a better Gross Margin (67.68%) than 74.60% of its industry peers.
In the last couple of years the Gross Margin of NXL has grown nicely.
NXL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.68% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.73%
GM growth 5Y2.21%
2. Health
2.1 Basic Checks
NXL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NXL has been increased compared to 1 year ago.
NXL has more shares outstanding than it did 5 years ago.
NXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
NXL has an Altman-Z score of 5.52. This indicates that NXL is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.52, NXL is in the better half of the industry, outperforming 79.89% of the companies in the same industry.
NXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.52 |
ROIC/WACCN/A
WACC8.75%
2.3 Liquidity
NXL has a Current Ratio of 10.44. This indicates that NXL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 10.44, NXL belongs to the top of the industry, outperforming 93.65% of the companies in the same industry.
A Quick Ratio of 10.15 indicates that NXL has no problem at all paying its short term obligations.
NXL's Quick ratio of 10.15 is amongst the best of the industry. NXL outperforms 94.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.44 | ||
| Quick Ratio | 10.15 |
3. Growth
3.1 Past
NXL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.78%.
The Revenue has grown by 16.46% in the past year. This is quite good.
NXL shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.05% yearly.
EPS 1Y (TTM)-2.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.82%
Revenue 1Y (TTM)16.46%
Revenue growth 3Y5.39%
Revenue growth 5Y-4.05%
Sales Q2Q%161.19%
3.2 Future
NXL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.65% yearly.
NXL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 95.89% yearly.
EPS Next Y19.67%
EPS Next 2Y16.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year34.3%
Revenue Next 2Y95.89%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NXL. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NXL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NXL's earnings are expected to grow with 16.65% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.65%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for NXL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.5
-0.03 (-1.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners7.53%
Inst Owner Change-0.08%
Ins Owners13.48%
Ins Owner Change5.82%
Market Cap27.29M
Revenue(TTM)174.80K
Net Income(TTM)-8850900
Analysts80
Price Target4.08 (172%)
Short Float %7.18%
Short Ratio0.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.62%
Min EPS beat(2)-48.51%
Max EPS beat(2)29.28%
EPS beat(4)1
Avg EPS beat(4)-60.01%
Min EPS beat(4)-131.02%
Max EPS beat(4)29.28%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)57%
Min Revenue beat(2)15.98%
Max Revenue beat(2)98.02%
Revenue beat(4)3
Avg Revenue beat(4)30.48%
Min Revenue beat(4)-10.89%
Max Revenue beat(4)98.02%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.69%
EPS NY rev (1m)0%
EPS NY rev (3m)16.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 156.09 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.58 | ||
| P/tB | 4.81 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0.01
BVpS0.33
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -134.84% | ||
| ROE | -148.42% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.68% | ||
| FCFM | N/A |
ROA(3y)-110.33%
ROA(5y)-801.91%
ROE(3y)-127.63%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.73%
GM growth 5Y2.21%
F-Score4
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 83.24% | ||
| Cap/Sales | 8.81% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.44 | ||
| Quick Ratio | 10.15 | ||
| Altman-Z | 5.52 |
F-Score4
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.82%
EPS Next Y19.67%
EPS Next 2Y16.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)16.46%
Revenue growth 3Y5.39%
Revenue growth 5Y-4.05%
Sales Q2Q%161.19%
Revenue Next Year34.3%
Revenue Next 2Y95.89%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-7.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.48%
OCF growth 3YN/A
OCF growth 5YN/A
NEXALIN TECHNOLOGY INC / NXL FAQ
Can you provide the ChartMill fundamental rating for NEXALIN TECHNOLOGY INC?
ChartMill assigns a fundamental rating of 3 / 10 to NXL.
What is the valuation status of NEXALIN TECHNOLOGY INC (NXL) stock?
ChartMill assigns a valuation rating of 0 / 10 to NEXALIN TECHNOLOGY INC (NXL). This can be considered as Overvalued.
How profitable is NEXALIN TECHNOLOGY INC (NXL) stock?
NEXALIN TECHNOLOGY INC (NXL) has a profitability rating of 1 / 10.
What is the financial health of NEXALIN TECHNOLOGY INC (NXL) stock?
The financial health rating of NEXALIN TECHNOLOGY INC (NXL) is 8 / 10.